{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Sonepcizumab",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).",
    "fdaUniiCode": "O4T5UXS4P2",
    "identifier": "C78195",
    "preferredName": "Sonepcizumab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C1742",
      "C20401"
    ],
    "synonyms": [
      "Asonep",
      "LT1009",
      "SONEPCIZUMAB",
      "Sonepcizumab"
    ]
  }
}